Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks Elocta's Long-Term joint protection in hemophilia

NCT ID NCT04293523

Disease control Sponsor: Swedish Orphan Biovitrum Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This 48-month study observes 427 people with hemophilia A who are already using Elocta to prevent bleeding. Researchers want to see how well the drug protects joints over time, including how many joint bleeds occur and whether target joints improve or worsen. The goal is to understand real-world effectiveness, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

427 people

The number who actually took part.

Started

Mar 2020

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed with haemophilia A regardless of severity, of any gender and age, on factor treatment with Elocta according to usual clinical practice.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provided signed and dated informed consent by the patient, or the patient's legally authorized representative(s) for patients under the legal age, before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations * Have a diagnosis of haemophilia A * At enrolment on prophylactic treatment with Elocta, independent of participation in the study Exclusion Criteria: * Enrolment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to inclusion in this study * Presence of factor VIII antibodies (inhibitors) (≥0.60 Bethesda Unit \[BU\]/mL) at the latest available inhibitor test

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemophilia A are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemophilia A

Contacts and locations

Locations

  • AUSL Romagna Centro Emofilia U.O.C., Medicina Trasfusionale Dipartimento Patologia, Clinica Ospedale M. Bufalini

    Cesena, Italy

  • Azienda Ospedaliera Città della Salute e della Scienza di Torino Regina Margherita

    Torino, Italy

  • Charité-Universitätsmedizin Berlin Campus Virchow Klinikum

    Berlin, Germany

  • Complejo Hospitalario de Navarra

    Navarro, Spain

  • Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital Malmö

    Malmö, Sweden

  • Dept. of Pediatric Haematology and Oncology, University Hospital Motol

    Prague, Czechia

  • Dr Suliman Al Habib Hospital Riyadh

    Riyadh, Saudi Arabia

  • East Kent Hospitals University NHS Foundation Trust, Kent Haemophilia and Thrombosis Centre, Kent and Canterbury Hospital

    Canterbury, United Kingdom

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Giannina Gaslini Institute

    Genova, Italy

  • Great Ormond Street Hospital, Royal London Hospital for Integrated Medicine

    London, United Kingdom

  • HZRM Hämöphilie Zentrum Rhein Main

    Mörfelden-Walldorf, Germany

  • Helsinki University Central Hospital, New Children Hospital

    Helsinki, Finland

  • Hematologimottagning Sahlgrenska

    Gothenburg, Sweden

  • Hospital Alvaro Cunqueiro

    Vigo, Spain

  • Hospital Universitario Carlos Haya

    Málaga, Spain

  • Hospital Universitario Central de Asturias (HUCA)

    Oviedo, Spain

  • Hospital Universitario Cruces

    Cruces, Spain

  • Hospital Universitario Donostia

    Donostia / San Sebastian, Spain

  • Hospital Universitario Son Espases

    Palma de Mallorca, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Spain

  • Hospital Vall d'Hebron

    Barcelona, Spain

  • Hospital Virgen de la Arrixaca

    Murcia, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hämostaseologie/Hämophiliezentrum, Medizinische Klinik 2 Institut für Transfusionsmedizin, Universitätsklinikum

    Frankfurt, Germany

  • Ippokrateio Hospital Thessaloniki (adult department)

    Thessaloniki, Greece

  • Ippokrateio Hospital Thessaloniki (pediatric department)

    Thessaloniki, Greece

  • Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital am Universitätsklinikum München

    München, Germany

  • King Faisal Specialised Hospital, KFSH Riyadh, Children

    Riyadh, Saudi Arabia

  • King Faisal Specialist Hospital KFSH, Adults

    Riyadh, Saudi Arabia

  • Lastehaigla, Tallinn (Tallinn Children´s Hospital)

    Tallinn, Estonia

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Riyadh Military Hospital (P.S.M.C)

    Riyadh, Saudi Arabia

  • SRH-Klinikum Heidelberg

    Heidelberg, Germany

  • Sant Johan De Deu

    Barcelona, Spain

  • Service et Laboratoire central d'hématologie, Adults

    Lausanne, Switzerland

  • The North Estonia Medical Centre Hematoloogiakeskus, Regionalhaigla

    Tallinn, Estonia

  • The Royal Hospital

    Muscat, Oman

  • Turku University Central Hospital, Paediatric and adolescent haematology and oncology clinic

    Turku, Finland

  • University Hospital Brno

    Brno, Czechia

  • University Hospital Ostrava

    Ostrava, Czechia

  • University Hospital of Parma, AOUP, Haemophilia Center

    Parma, Italy

  • University Medical Center Groningen/UMCG

    Groningen, Netherlands

  • University Medical Centre Ljubljana Division of Paediatrics

    Ljubljana, Slovenia

  • University of Bari Aldo Moro (Centro Emofilia Policlinico - Pediatria U.O.)

    Bari, Italy

  • Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor Inselspital

    Bern, Switzerland

  • Universitätsklinikum Bonn AöR, Institut für Experimentelle Hämatologie und Transfusionsmedizin

    Bonn, Germany

  • Universitätsklinikum Frankfurt - Klinik für Kinder- und Jugendmedizin

    Frankfurt, Germany

  • Universitätsklinikum Hamburg-Eppendorf (UKE)

    Hamburg, Germany

  • Universitätsspital Zürich Klinik für Medizinische Onkologie und Hämatologie

    Zurich, Switzerland

  • Uo Malattie Emorragiche e Trombotiche Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Universitá Catolica del Sacro Coure

    Rome, Italy

  • Werlhof-Institut für Hämostaseologie GmbH

    Hanover, Germany

  • Zentrum für Labormedizin

    Sankt Gallen, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.